<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99213">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995058</url>
  </required_header>
  <id_info>
    <org_study_id>XL184-210</org_study_id>
    <nct_id>NCT01995058</nct_id>
  </id_info>
  <brief_title>Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <official_title>A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exelixis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and efficacy of combining abiraterone (with
      prednisone) with cabozantinib in chemotherapy-naïve subjects with bone-metastatic
      castration-resistant prostate cancer (CRPC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Radiographic progression free survival (PFS)</measure>
    <time_frame>Up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS is defined as the time from randomization to the earlier of the following events: disease progression or death due to any cause</description>
  </primary_outcome>
  <other_outcome>
    <measure>Safety and tolerability as assessed by adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects are followed for safety as assessed by adverse events at least through 30 days after the date of a decision to permanently discontinue study treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Pre-dose Plasma Concentrations of both cabozantinib and abiraterone when administered in combination</measure>
    <time_frame>Days 1-4, Week 3, Week 5, Week 7, Week 9, Week 17, and Week 41</time_frame>
    <safety_issue>No</safety_issue>
    <description>When administered in combination, both cabozantinib and abiraterone plasma concentrations will be measured prior to dosing on selected visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival is defined as the time from randomization to death from any cause.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bone scan response by computer-aided detection (CAD)</measure>
    <time_frame>Up to 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bone scans will be evaluated by an independent radiology facility for response</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Plasma Area Under the Curve (AUC)</measure>
    <time_frame>Week 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>For selected subjects, the plasma AUC of cabozantinib and abiraterone will be measured at Week 5</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Castration Resistant Prostate Cancer</condition>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cabozantinib arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive cabozantinb 40 mg daily with abiratarone and prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabozantinib arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive cabozantinib 20 mg daily with abiraterone and prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabozantinib arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive cabozantinb 20 mg every other day with abiraterone and prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone only arm (4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive abiraterone with prednisone only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabozantinib</intervention_name>
    <description>Tablets taken orally</description>
    <arm_group_label>Cabozantinib arm 1</arm_group_label>
    <arm_group_label>Cabozantinib arm 2</arm_group_label>
    <arm_group_label>Cabozantinib arm 3</arm_group_label>
    <other_name>XL184</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abiraterone</intervention_name>
    <description>Tablets taken orally daily</description>
    <arm_group_label>Cabozantinib arm 1</arm_group_label>
    <arm_group_label>Cabozantinib arm 2</arm_group_label>
    <arm_group_label>Cabozantinib arm 3</arm_group_label>
    <arm_group_label>Abiraterone only arm (4)</arm_group_label>
    <other_name>Zytiga(R)</other_name>
    <other_name>abiraterone acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>Tablets taken orally twice daily</description>
    <arm_group_label>Cabozantinib arm 1</arm_group_label>
    <arm_group_label>Cabozantinib arm 2</arm_group_label>
    <arm_group_label>Cabozantinib arm 3</arm_group_label>
    <arm_group_label>Abiraterone only arm (4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate.

          -  Must be surgically or medically castrated (serum testosterone levels less than or
             equal to 50 ng/dL)

          -  Must have castration-resistant prostate cancer (CRPC) with disease progression during
             LHRH therapy or after a surgical bilateral orchiectomy.

          -  Bone metastasis related to prostate cancer

          -  Adequate organ and marrow function

          -  Capable of understanding and complying with the protocol requirements and signed the
             informed consent document

          -  Sexually active subjects and their partners must agree to use medically accepted
             methods of barrier contraception (eg, male condom or female condom) as well as one
             other medically accepted method of contraception during the course of the study
             treatment and for 4 months after the last dose of study treatment.

        Exclusion Criteria:

          -  Any prior treatment with abiraterone, enzalutamide, or any investigational agents
             blocking androgen receptor (AR) or androgen synthesis.

          -  Any prior treatment with cabozantinib or participation in a prior clinical trial of
             cabozantinib.

          -  Any prior cytotoxic therapy (including estramustine) or biologic therapy for the
             treatment of prostate cancer (a few exceptions will be allowed)

          -  Any prior radionuclide therapy (eg, samarium 153, strontium 89, alpharadin)

          -  Use of investigational agent within 28 days

          -  Any pathological finding consistent with small cell carcinoma of the prostate

          -  Known brain metastases or cranial epidural disease

          -  Diagnosis of another malignancy within 2 years, except for superficial non-melanoma
             skin cancers, or localized, low grade tumors deemed cured and not treated with
             systemic therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Exelixis Clinical Trials</last_name>
    <phone>1-888-393-5494</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deana Garrett</last_name>
      <phone>480-860-5000</phone>
      <email>dgarrett@azpoh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Sedona</city>
        <state>Arizona</state>
        <zip>86336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Drennen</last_name>
      <phone>281-863-4689</phone>
      <email>Tracy.Drennan@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Klinker</last_name>
      <phone>520-269-3821</phone>
      <email>Julie.Klinker@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Drennen</last_name>
      <phone>281-863-4689</phone>
      <email>Tracy.Drennan@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Morris</last_name>
      <phone>303-418-7669</phone>
      <email>karen.morris@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Wacker</last_name>
      <phone>720-848-4020</phone>
      <email>mike.wacker@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Melink</last_name>
      <phone>706-353-2990</phone>
      <phone_ext>284</phone_ext>
      <email>mmelink@negacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Johnston</last_name>
      <phone>678-298-3235</phone>
      <email>ajohnston@piedmontcancerinstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Williams</last_name>
      <phone>309-243-3614</phone>
      <email>nwilliams@illinoiscancercare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pat Stone</last_name>
      <phone>316-613-4313</phone>
      <email>pat.stone@cancercenterofkansas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Drennen</last_name>
      <phone>281-863-4689</phone>
      <email>Tracy.Drennan@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy DeWitt</last_name>
      <phone>919-571-7436</phone>
      <email>amy.dewitt2@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamyra Batsch</last_name>
      <phone>360-597-1358</phone>
      <email>Tamyra.Batsch@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah McNeal</last_name>
      <phone>843-266-2540</phone>
      <email>d.mcneal@choasc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Norris</last_name>
      <phone>864-242-2762</phone>
      <email>gnorris@ghs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Harrelson</last_name>
      <phone>843-286-0119</phone>
      <email>sharrelson@atlanticurologyclinics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Drennen</last_name>
      <phone>281-863-4689</phone>
      <email>Tracy.Drennan@mckesson.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Renard</last_name>
      <phone>713-467-1722</phone>
      <email>jamie.renard@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dholani Zarook</last_name>
      <phone>801-587-4776</phone>
      <email>dholani.zarook@hci.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>November 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRPC</keyword>
  <keyword>castration resistant prostate cancer</keyword>
  <keyword>prostate cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
